SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$4.64 USD
0.00 (0.00%)
Updated May 15, 2024 04:00 PM ET
After-Market: $4.69 +0.05 (1.08%) 6:48 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
SOPH 4.64 0.00(0.00%)
Will SOPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SOPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SOPH
Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
SOPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Other News for SOPH
SOPHiA GENETICS Triumphs with AI-Driven Growth
SOPHiA GENETICS SA (SOPH) Q1 2024 Earnings Call Transcript
Sophia Genetics management to meet with BTIG
SOPHiA GENETICS SA 2024 Q1 - Results - Earnings Call Presentation
RBC Capital Remains a Buy on SOPHiA GENETICS (SOPH)